Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Authors

Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

9-12-2023

Volume

7

Issue

17

First Page

4926

Last Page

4935

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2022009260

Rights and Permissions

Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Bartlett, Nancy L and et al., "Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma." Blood Advances. 7, 17. 4926 - 4935. (2023).
https://digitalcommons.wustl.edu/oa_4/2197

Additional Links

Supplemental material is available for this article at publisher site.